Exelixis | EXEL - Ebit

Stock Price
43.94
Daily Change
0.06 0.14%
Monthly
3.71%
Yearly
26.12%
Q2 Forecast
42.56

Exelixis reported $235.91M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bayer EUR 1.11B 1.51B Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Genmab DKK 260M 199M Dec/2025
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
MacroGenics USD -12.1M 32.26M Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Moderna USD -857M 597M Dec/2025
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.06B 530M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Sanofi EUR 3.74B 2.23B Sep/2025
Takeda JPY 257.49B 568.56B Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025